• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How First SiRNA Candidate Will Impact XtalPi Holdings Stock Investors

    Simply Wall St·10/20/2026 17:29:37
    Listen to the news
    • XtalPi Holdings recently nominated its first internally developed siRNA preclinical candidate for immunoglobulin A nephropathy, using its Kodexia platform to complete discovery in nine months and report strong potency, durability, and safety signals in early in vitro and non human primate work.
    • The program highlights how Kodexia jointly optimizes siRNA sequence and chemistry in a closed loop of AI design and automated experiments, aiming to compress timelines and potentially improve hit quality across multiple nucleic acid pipelines.
    • Next, the focus turns to how this Kodexia powered siRNA milestone may reshape XtalPi Holdings' broader investment narrative and risk profile.
    Spot opportunities across AI driven drug discovery by scanning our hand picked 122 healthcare AI stocks that echo the Kodexia story in XtalPi Holdings.

    What Is XtalPi Holdings' Investment Narrative?

    For an investor to stay with XtalPi Holdings, the belief has to be that its AI for Science tools and drug discovery services can scale into a much larger commercial engine, and that the newer siRNA programs become a second pillar rather than an expensive side project. The Kodexia powered IgAN candidate is important in that context because it shows the platform producing a concrete asset with subnanomolar potency and encouraging non human primate durability, which speaks directly to execution, not just slideware.

    In the near term, the practical questions are about funding and discipline. XtalPi Holdings generated HK$679.2m of revenue but still reported a loss of CN¥210.9m, trades on a rich 32.8x P/S against an industry multiple of 4.5x, and the share price has fallen 49% over the past year. The Kodexia news may strengthen the story around high forecast revenue and earnings growth, yet it also increases capital intensity and R&D burden at a time when returns on equity are low and the stock already screens as expensive versus both peers and estimated cash flow value.

    All of that sits next to one awkward complication that could matter much more if the Kodexia pipeline hits a bump.

    There's only one way to know the right time to buy, sell or hold XtalPi Holdings. Head to Simply Wall St's company report for the latest analysis of XtalPi Holdings's Fair Value.

    SEHK:2228 1-Year Stock Price Chart
    SEHK:2228 1-Year Stock Price Chart

    Exploring Other Perspectives

    Two fair value estimates from the Simply Wall St Community span a wide band, from 0.57x to 9.93x the current XtalPi Holdings share price. This shows how far apart retail views already sit. With Kodexia and the IgAN siRNA candidate still in early stages, you are watching investors reprice execution risk and optionality in real time.

    Explore another XtalPi Holdings fair value estimate, including one that suggests as much as 91% downside from the current price!

    Form Your Own Verdict

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your XtalPi Holdings research is our analysis highlighting 1 key reward that could impact your investment decision.
    • See our latest analysis for XtalPi Holdings. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate XtalPi Holdings' overall financial health at a glance.

    Looking For More Investment Ideas Beyond XtalPi Holdings?

    If the XtalPi Holdings story has sharpened your thinking but you want a broader watchlist, the Simply Wall St screener can help you quickly filter for stocks that better match your risk appetite and return goals.